References

1. Coons, S. W., Johnson, P. C., and Shapiro, J. R. (1995). Cytogenetic and flow cytometry, DNA analysis of regional heterogeneity in a low grade glioma. Cancer Res 55, 1569-1577.

2. Scheck, A. C., Shapiro, J. R., Coons, S. W., Norman, S. A., and Johnson, P. C. (1996). Biological and molecular analysis of a low grade recurrence of a glioblastoma multiforme. Clin Cancer Res 2, 187-199.

3. Scheck, A. C., Shapiro, J. R., Ballacer, C. et al. (1996). Clonal analysis of human malignant glioma cells selected for resistance to BCNU. Proceedings of the American Association for Cancer Research 37, 338.

4. Maintz, D., Fiedler, K., Koopmann, J. et al. (1997). Molecular genetic evidence for subtypes of oligoastrocytomas. Neuropathol Exp Neurol 56, 1098-1104.

5. von Deimling, A., Louis, D. N., von Ammon, K. et al. (1992) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77, 295-301.

6. von Deimling, A., Louis, D. N., Schramm, J., and Wiestler, O. D. (1994). Astrocytic gliomas: characterization on a molecular genetic basis. Recent Results in Cancer Res 135, 33-42.

7. von Deimling, A., Louis, D. N., and Wiestler, O. D. (1995). Molecular pathways in the formation of gliomas. Glia 15, 328-338.

8. Shapiro, J. R. (1986). Cellular characterization and BCNU resistance of freshly resected and early passage human glioma cells. Progress in Neuropathology 6, 133-143.

9. Scheck, A. C., Mehta, B. M., Beikman, M. K., and Shapiro, J. R. (1993). BCNU-resistant human glioma cells with over-representation of chromosomes 7 and 22 demonstrate increased copy number and expression of platelet-derived growth factor genes. Genes, Chromosomes & Cancer 8, 137-148.

10. Drablos, F., Feyzi, E., Aas, P. A. et al. (2004). Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 3, 1389-1407.

11. Margison, G. P., and Santibanez-Koref, M. F. (2002). O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. BioEssays 24, 255-266.

12. Perez, R. P., Hamilton, T. C., and Ozols, R. F. (1990). Resistance to alkylating agents and cisplatin: Insights from ovarian carcinoma model systems. Pharmac Ther 48, 19-27.

13. Schold, S. C., Jr., Brent, T. P., Von Hofe, E. et al. (1989). O6-alkylguanine-DNA alkyltransferase and sensitivity to procarba-zine in human brain-tumor xenografts. J Neurosurg 70, 573-577.

14. Silber, J. R., Blank, A., Bobola, M. S., Ghatan, S., Kolstoe, D. D., and Berger, M. S. (1999). O6-methylguanine-DNA methyltrans-ferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5, 807-814.

15. Friedman, H. S. (2000). Can O6-alkylguanine-DNA alkyltrans-ferase depletion enhance alkylator activity in the clinic? Clin Cancer Res 6, 2967-2968.

16. Ludlum, D. B. (1990). DNA alkylation by the haloethylnitro-soureas: Nature of modifications produced and their enzymatic repair or removal. Mutat Res Fundam Mol Mech Mutagen 233, 117-126.

17. Gerson, S. L. (2002). Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20, 2388-2399.

18. Wang, D., and Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4, 307-320.

19. Fedier, A., and Fink, D. (2004). Mutations in DNA mismatch repair genes: Implications for DNA damage signaling and drug sensitivity (Review). Int J Cancer 24, 1039-1047.

20. Aebi, S., Kurdi-Haidar, B., Gordon, R. et al. (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56, 3087-3090.

21. Fink, D., Nebel, S., Aebi, S. et al. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56, 4881-4886.

22. Fink, D., Zheng, H., Nebel, S. et al. (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57, 1841-1845.

23. Fink, D., Aebi, S., and Howell, S. B. (2000). The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4, 1-6.

24. Asselin, E., Mills, G. B., and Tsang, B. K. (2001). XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61, 1862-1868.

25. Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., and Kohn, K. W. (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23, 2934-2949.

26. Cloughesy, T. F., Filka, E., Kuhn, J. et al. (2003). Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97, 2381-2386.

27. Prados, M. D., Yung, W. K., Jaeckle, K. A. et al. (2004). Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol 6, 44-54.

28. Reardon, D. A., Friedman, H. S., Powell, J. B., Jr., Gilbert, M., and Yung, W. K. (2003). Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Huntingt) 17, 9-14.

29. Reardon, D. A., Quinn, J. A., Rich, J. N. et al. (2004). Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neurooncol 6, 134-144.

30. Reardon, D. A., Quinn, J. A., Vredenburgh, J. et al. (2005). Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103, 329-338.

31. Parker, R. J., Fruehauf, J. P., Mehta, R., Filka, E., and Cloughesy, T. (2004). A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 66, 365-375.

32. Kanzawa, F., Sugimoto, Y., Minato, K. et al. (1990). Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50, 5919-5924.

33. Kubota, N., Kanzawa, F., Nishio, K. et al. (1992). Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 188, 571-577.

34. Pratt, W. B., Ruddon, R. W., Ensminger, W. D., and Maybaum, J. (1994). Inhibitors of Chromatin Function. In The Anticancer Drugs. pp. 183-198. Oxford Universtiy Press, New York.

35. Parney, I. F., and Chang, S. M. (2003). Current chemotherapy for glioblastoma. Cancer J 9, 149-156.

36. Beauchesne, P., Soler, C., Boniol, M., and Schmitt, T. (2003). Response to a phase II study of concomitant-to-sequential use of etoposide and radiation therapy in newly diagnosed malignant gliomas. Am J Clin Oncol 26, e22-e27.

37. Fagioli, F., Biasin, E., Mastrodicasa, L. et al. (2004). High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer 100, 2215-2221.

38. Fiorillo, A., Maggi, G., Greco, N. et al. (2004). Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. J Neurooncol. 66, 179-185.

39. Franceschi, E., Cavallo, G., Scopece, L. et al. (2004). Phase II trial of carboplatin and etoposide for patients with recurrent highgrade glioma. Br.J Cancer 91, 1038-1044.

40. Korones, D. N., Benita-Weiss, M., Coyle, T. E. et al. (2003). Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97, 1963-1968.

41. Lopez-Aguilar, E., Sepulveda-Vildosola, A. C., Rivera-Marquez, H. et al. (2003). Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astro-cytomas in children. Childs Nerv Syst 19, 818-823.

42. Rao, R. D., Krishnan, S., Fitch, T. R. et al. (2005). Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys 61, 380-386.

43. Rutkowski, S., Bode, U., Deinlein, F. et al. (2005). Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352, 978-986.

44. Wolff, J. E., Westphal, S., Molenkamp, G. et al. (2002). Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87, 945-949.

45. Wolff, J. E., and Finlay, J. L. (2004). High-dose chemotherapy in childhood brain tumors. Onkologie 27, 239-245.

46. Matsumoto, Y., Tamiya, T., and Nagao, S. (2005). Resistance to topoisomerase II inhibitors in human glioma cell lines over-expressing multidrug resistant associated protein (MRP) 2. J Med Invest 52, 41-48.

47. Benyahia, B., Huguet, S., Decleves, X. et al. (2004). Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 66, 65-70.

48. Fornace, A. J., Papathanasiou, M. A., Hollander, M. C., and Yarosh, D. B. (1990). Expression of the O6-methylguanine-DNA methyltransferasa gene MGMT in MER+ and MER—<human tumor cells. Cancer Res 50, 7908-7911.

49. Gerson, S. L. (2004). MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4, 296-307.

50. Phillips, W. P., Jr., Willson, J. K. V., Markowitz, S. D. et al. (1997). O6-methylguanine-DNA methyltransferase (MGMT) transfec-tants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogeneous MGMT+/MGMT—<xenografts after BCNU and O6-benzylgua-nine plus BCNU. Cancer Res 57, 4817-4823.

51. Ali-Osman, F., Srivenugopal, K., and Sawaya, R. (2001). The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 344, 687-688.

52. Kaina, B., and Christmann, M. (2002). DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40, 354-367.

53. Esteller, M., Garcia-Foncillas, J., Andion, E. et al. (2000). Inacti-vation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343, 1350-1354.

54. Blancato, J. K., Wager, M., Guilhot, J. et al. (2004). Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68, 275-283.

55. Hegi, M. E., Diserens, A. C., Gorlia, T. et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.

56. Mollemann, M., Wolter, M., Felsberg, J., Collins, V. P., and Reifenberger, G. (2005). Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113, 379-385.

57. Hirose, Y., Kreklau, E. L., Erickson, L. C., Berger, M. S., and Pieper, R. O. (2003). Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98, 591-598.

58. Houghton, P. J., Stewart, C. F., Cheshire, P. J. et al. (2000). Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltrans-ferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6, 4110-4118.

59. Srivenugopal, K. S., Shou, J., Mullapudi, S. R., Lang, F. F., Jr., Rao, J. S., and Ali-Osman, F. (2001). Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylgua-nine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 7, 1398-1409.

60. Paz, M. F., Yaya-Tur, R., Rojas-Marcos, I. et al. (2004). CpG island hypermethylation of the DNA repair enzyme methyl-transferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10, 4933-4938.

61. Esteller, M., and Herman, J. G. (2004). Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23, 1-8.

62. Hegi, M. E., Diserens, A. C., Godard, S. et al. (2004). Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10, 1871-1874.

63. Stupp, R., Mason, W. P., van den Bent, M. J. et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.

64. Rood, B. R., Zhang, H., and Cogen, P. H. (2004). Intercellular heterogeneity of expresison of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro-oncol 6, 200-207.

65. Zuo, C., Ai, L., Ratliff, P. et al. (2004). O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13, 967-975.

66. Hickman, M. J., and Samson, L. D. (1999). Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96, 10764-10769.

67. Biroccio, A., Bufalo, D. D., Ricca, A. et al. (1999). Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther 6, 1064-1072.

68. Middlemas, D. S., Stewart, C. F., Kirstein, M. N. et al. (2000). Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6, 998-1007.

69. Xu, G. W., Nutt, C. L., Zlatescu, M. C., Keeney, M., Chin-Yee, I., and Cairncross, J. G. (2001). Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 61, 4155-4159.

70. Bocangel, D. B., Finkelstein, S., Schold, S. C., Bhakat, K. K., Mitra, S., and Kokkinakis, D. M. (2002). Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8, 2725-2734.

71. Rolhion, C., Penault-Llorca, F., Kemeny, J. L. et al. (1999). O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characterisitics and p53 accumulation. Int J Cancer 84, 416-420.

72. Bello, M. J., Alonso, M. E., Aminoso, C. et al. (2004). Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutat Res 554, 23-32.

73. Nakamura, M., Watanabe, T., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2001). Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C !<A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22, 1715-1719.

74. Dolan, M. E., Stine, L., Mitchell, R. B., Moschel, R. C., Pegg, A. E. (1990). Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1- nitrosourea. Cancer Communications 2, 371-377.

75. Dolan, M. E., Chae, M.-Y., Pegg, A. E., Mullen, J. H., Friedman, H. S., and Moschel, R. C. (1994). Metabolism of O6-benzylgua-nine, an inactivator of O6- alkylguanine-DNA alkyltransferase. Cancer Res 54, 5123-5130.

76. Dolan, M. E., and Pegg, A. E. (1997). O6-Benzylguanine and its role in chemotherapy. Clinical Cancer Res 3, 837-847.

77. Pegg, A. E., Boosalis, M., Samson, L. et al. (1993). Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransfer-ase by O6-benzylguanine. Biochemistry 32, 11998-12006.

78. Chen, J.-M., Zhang, Y.-P., Moschel, R. C., and Ikenaga, M. (1993). Depletion of O6-methylguanine-DNA methyltransferase and potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea antitumor activity by O6-benzylguanine in vitro. Carcinogenesis 14, 1057-1060.

79. Dolan, M. E., Pegg, A. E., Moschel, R. C., and Grindey, G. B. (1993). Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 46, 285-290.

80. Felker, G. M., Friedman, H. S., Dolan, M. E., Moschel, R. C., and Schold, C. (1993). Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32, 471-476.

81. Kokkinakis, D. M., Bocangel, D. B., Schold, S. C., Moschel, R. C., and Pegg, A. E., (1907). Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 2001 421-428.

82. Kokkinakis, D. M., Ahmed, M. M., Chendil, D., Moschel, R. C., and Pegg, A. E. (2003). Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine. Clin Cancer Res 9, 3801-3807.

83. Mitchell, R. B., Moschel, R. C., and Dolan, M. E. (1992). Effect of O6-benzylguanine on the sensitivity of human tumor xeno-grafts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res 52, 1171-1175.

84. Sarkar, A., Dolan, M. E., Gonzalez, G. G., Marton, L. J., Pegg, A. E., and Deen, D. F. (1993). The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol 32, 477-481.

85. Srivenugopal, K. S., Yuan, X. H., Friedman, H. S., and Ali-Osman, F. (1996). Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35, 1328-1334.

86. Wedge, S. R., and Newlands, E. S. (1973). O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolo-mide and BCNU. Br J Cancer 1996 1049-1052.

87. Wedge, S. R., Porteous, J. K., and Newlands, E. S. (1974). 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996 1030-1036.

88. Friedman, H. S., Keir, S., Pegg, A. E. et al. (2002). O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1, 943-948.

89. Kanzawa, T., Bedwell, J., Kondo, Y., Kondo, S., and Germano, I. M. (2003). Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99, 1047-1052.

90. Neville, K., Blaney, S., Bernstein, M. et al. (2004). Pharmaco-kinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res 10, 5072-5075.

91. Dolan, M. E., Posner, M., Karrison, T. et al. (2002). Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res 8, 2519-2523.

92. Friedman, H. S., Kokkinakis, D. M., Pluda, J. et al. (1998). Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16, 3570-3575.

93. Friedman, H. S., Pluda, J., Quinn, J. A. et al. (2000). Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18, 3522-3528.

94. Schilsky, R. L., Dolan, M. E., Bertucci, D. et al. (2000). Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 6, 3025-3031.

95. Schold, S. C., Jr., Kokkinakis, D. M., Chang, S. M. et al. (2004). O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro-oncol 6, 28-32.

96. Spiro, T. P., Gerson, S. L., Liu, L. et al. (1999). O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59, 2402-2410.

97. Bacolod, M. D., Johnson, S. P., Ali-Osman, F. et al. (2002). Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyo-sarcoma. Mol Cancer Ther 1, 727-736.

98. Bacolod, M. D., Johnson, S. P., Pegg, A. E. et al. (2004). Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkyl-guanine-DNA alkyltransferase mutations. Mol Cancer Ther 3, 1127-1135.

99. Crone, T. M., and Pegg, A. E. (1993). A single amino acid change in human O6-alkylguanine-DNA alkyltransferase decreasing sensitivity to inactivation by O6-benzylguanine. Cancer Res 53, 4750-4753.

100. Crone, T. M., Kanugula, S., and Pegg, A. E. (1995). Mutations in the Ada O6-alkylguanine-DNA alkyltransferase conferring sensitivity to inactivation by O6-benzylguanine and 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine. Carcinogenesis 16, 1687-1692.

101. Xu-Welliver, M., Leitao, J., Kanugula, S., Meehan, W. J., and Pegg, A. E. (1999). Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzyl-guanine. Biochem Pharmacol 58, 1279-1285.

102. Ueda, S., Mineta, T., Nakahara, Y. et al. (2004). Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas. J Neurosurg 101, 659-663.

103. Marathi, U. K., Dolan, M. E., and Erickson, L. C. (1994). Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol 48, 2127-2134.

104. Karran, P. (2001). Mechanisms of tolerance to DNA damaging therapeutic agents. Carcinogenesis 22, 1931-1937.

105. Liu, L., Markowitz, S., and Gerson, S. L. (1996). Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. Cancer Res 56, 5375-5379.

106. Pepponi, R., Marra, G., Fuggetta, M. P. et al. (2003). The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304, 661-668.

107. Christmann, M., and Kaina, B. (2000). Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J Biol Chem 275, 36256-36262.

108. Rellecke, P., Kuchelmeister, K., Schachenmayr, W., and Schlegel, J. (2004). Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas. J Neurosurg 101, 653-658.

109. Luo, M., and Kelley, M. R. (2004). Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 24, 2127-2134.

110. Friedman, H. S., Johnson, S. P., Dong, Q. et al. (1997). Methyl-ator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57, 2933-2936.

111. Francia, G., Man, S., Teicher, B., Grasso, L., and Kerbel, R. S. (2004). Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 24, 6837-6849.

112. Bignami, M., Casorelli, I., and Karran, P. (2003). Mismatch repair and response to DNA-damaging antitumor therapies. Eur J Cancer 39, 2149.

113. Meyers M., Hwang A., Wagner, M. W., and Boothman, D. A. (2004). Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 44, 249-264.

114. Mello, J. A., Acharya, S., Fishel, R., and Essigmann, J. M. (1996). The mismatch-repair protein hMSH2 binds selctively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3, 579-589.

115. Papouli, E., Cejka, P., and Jiricny, J. (2004). Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 64, 3391-3394.

116. Branch, P., Masson, M., Aquilina, G., Bignami, M., and Karran, P. (2000). Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 19, 3138-3145.

117. Srivastava, T., Chattopadhyay, P., Mahapatra, A. K., Sarkar, C., and Sinha, S. (2004). Increased hMSH2 protein expression in glioblastoma multiforme. J Neurooncol 66, 51-57.

118. Lage, H., Christmann, M., Kern, M. A. et al. (1999). Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpur-ine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 80, 744-750.

119. Bearzatto, A., Szadkowski, M., Macpherson, P., Jiricny, J., and Karran, P. (2000). Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 60, 3262-3270.

120. Kirkpatrick, D. T., and Petes, T. D. (1997). Repair of DNA loops involves DNA-mismatch and nucleotide-excision repair proteins. Nature 387, 929-931.

121. Moggs, J. G., Szymkowski, D. E., Yamada, M., Karran, W., and Wood, R. D. (1997). Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res 25, 480-490.

122. Hoeijmakers, J. H. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374.

123. Lodish, H., Berk, A., Matsudaira, P. et al. (2004). Cancer. In Molecular Cell Biology. pp. 935-973. W. H. Freeman and Company, New York.

124. Chaney, S. G., and Sancar, A. (1996). DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88, 1346-1360.

125. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. (1999). Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59, 3968-3971.

126. Tentori, L., Portarena, I., Torino, F., Scerrati, M., Navarra, P., and Graziani, G. (2002). Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. GHa 40, 44-54.

127. Curtin, N. J., Wang, L. Z., Yiakouvaki, A. et al. (2004). Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10, 881-889.

128. Stoehlmacher, J., Park, D. J., Zhang, W. et al. (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94, 936-942.

129. Britten, R. A., Green, J. A., and Warenius, H. M. (1992). Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol, Biol, Phy 24, 527-531.

130. Evans, C. G., Bodell, W. J., Tokuda, K., Doane-Setzer, P., and Smith, M. T. (1987). Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard. Cancer Res 47, 2525-2530.

131. Hara, A., Yamada, H., Sakai, N., Hirayama, H., Tanaka, T., and Mori, H. (1990). Immunohistochemical demonstration of the placental form of glutathione S-transferase,a detoxifying enzyme in human gliomas. Cancer 66, 2563-2568.

132. Smith, M. T., Evans, C. G., Doane-Setzer, P., Castro, V. M., Tahir, M. K., and Mannervik, B. (1989). Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferase and its role in cellular resistance in rat brain tumor cells. Cancer Res 49, 2621-2625.

133. Waxman, D. J. (1990). Glutathione S-transferases: Role in alkylating agent resistance and possible target for modulation chemotherapy - a review. Cancer Res 50, 6449-6454.

134. Yang, W. Z., Begleiter, A., Johnston, J. B., Israels, L. G., and Mowat, M. R. A. (1991). The role of glutathione (GSH) and glutathione S-transferase (GST) in Chlorambucil (CLB) resistance. Proceedings of the American Association for Cancer Research 32, 360.

135. Hayes, J. D., and Pulford, D. J. (1995). The glutathione S-Transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30, 445-600.

136. Yamayoshi, Y., Iida, E., and Tanigawara, Y. (2005). Cancer Pharmacogenomics: international trends. The Japan Society of Clinical Oncology 10, 5-13.

137. Ali-Osman, F., Stein, D. E., and Renwick, A. (1990). Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. Cancer Res 50, 6976-6980.

138. Brandt, T. Y., and Ali-Osman, F. (1997). Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells. Toxicol Appl Pharmacol 22-29.

139. Wang, Y., Teicher, B. A., Shea, T. C. et al. (1989). Cross-resistance and glutathione-S-transferase-n levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res 49, 6182-6192.

140. Lien, S., Larsson, A. K., and Mannervik, B. (2002). The polymorphic human glutathione transferase T1-1, the most efficient glutathione transferase in the denitrosation and 156. inactivation of the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochem Pharmacol 63, 191-197.

141. Winter, S., Strik, H., Rieger, J., Beck, J., Meyermann, R., and

Weller, M. (2000). Glutathione S-transferase and drug 157. sensitivity in malignant glioma. J Neurol Sci 179, 115-121.

142. Ali-Osman, F., Antoun, G., Wang, H., Rajagopal, S., and Gagucas, E. (1996). Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, 158. kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. Mole Pharmacol 49, 159. 1012-1020.

143. Ali-Osman, F., Caughlan, J., and Gray, G. S. (1989). Decreased

DNA interstrand cross-linking and cytotoxicity induced in 160. human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitro-sourea after in vitro reaction with glutathione. Cancer Res 49(21), 5954-5958.

144. Ali-Osman, F., Brunner, J. M., Kutluk, T. M., and Hess, K. 161. (1997). Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas.

Clin Cancer Res 3, 2253-2261. 162.

145. Norman, S. A., Rhodes, S. N., Treasurywala, S., Hoelzinger, D. B., Shapiro, J. R., and Scheck, A. C. (2000). Identification of transforming growth factor-beta1 binding protein over- 163. expression in BCNU-resistant glioma cells by differential mRNA display. Cancer 89, 850-862.

146. Ali-Osman, F., Akande, O., Antoun, G., Mao, J. X., and Buolamwini, J. (1997). Molecular cloning, characterization, 164. and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded 165.

proteins. J Biol Chem 272, 10004-10012.

147. Strange, R. C., Jones, P. W., and Fryer, A. A. (2000). Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 112-113, 357-363. 166.

148. Iyer, L., and Ratain, M. J. (1998). Pharmacogenetics and cancer chemotherapy. Eur J Cancer 34, 1493-1499.

149. Pemble, S., Schroeder, K. R., Spencer, S. R. et al. (1994). Human glutathione S-transferase theta (GSTT1): cDNA cloning and 167. the characterization of a genetic polymorphism. Biochem J 300, 271-276.

150. Ezer, R., Alonso, M., Pereira, E. et al. (2002). Identification of 168. glutathione S-transferase (GST) polymorphisms in brain tumors and assocation with susceptibility to pediatric astro-cytomas. J Neurooncol 59, 123-134. 169.

151. Pinarbasi, H., Silig, Y., and Gurelik, M. (2005). Genetic polymorphisms of GSTs and their association with primary brain tumor incidence. Cancer Genet Cytogenet 156, 144-149.

152. Wrensch, M., Kelsey, K. T., Liu, M. et al. (2004). Glutathione-S-transferase variants and adult glioma. Cancer Epidemiol 170. Biomarkers Prev 13, 461-467.

153. De Roos, A. J., Rothman, N., Inskip, P. D. et al. (2003). Genetic polymorphisms in GSTM1, -P1, -T1, adn CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 12, 171. 14-22.

154. Yang, G., Shu, X. O., Ruan, Z. X. et al. (2005). Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive 172. breast carcinoma. Cancer 103, 52-58.

155. Howells, R. E., Dhar, K. K., Hoban, P. R. et al. (2004). Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial 173. ovarian cancer. Int J Gynecol Cancer 14, 242-250.

Sweeney, C., Nazar-Stewart, V., Stapleton, P. L., Eaton, D. L., and Vaughan, T. L. (2003). Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12, 527-533. Cabelguenne, A., Loriot, M. A., Stucker, I. et al. (2001). Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 93, 725-730. Okcu, M. F., Selvan, M., Wang, L. -E. et al. (2004). Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clinical Cancer Res 10, 2618-2625. Tanaka, S., Kobayashi, I., Oka, H. et al. (2001). Drug-resistance gene expression and progression of astrocytic tumors. Brain Tumor Pathol 18, 131-137.

Peters, U., Preisler-Adams, S., Hebeisen, A. et al. (2000). Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11, 639-643.

Theocharis, S. E., Margeli, A. P., Klijanienko, J. T., and Kouraklis, G. P. (2004). Metallothionein expression in human neoplasia. Histopathology 45, 103-118.

Shimoda, R., Achanzar, W. E., Qu, W. et al. (2003). Metal-lothionein is a potential negative regulator of apoptosis. Toxicol Sci 73, 294-300.

Tews, D. S., Fleissner, C., Tiziani, B., and Gaumann, A. K.

(2001). Intrinsic expression of drug resistance-associated factors in meningiomas. Appl Immunohistochem Mol Morphol 9, 242-249.

Maier, H., Jones, C., Jasani, B. et al. (1997). Metallothionein overexpression in human brain tumours. Acta Neuropathol (Berl) 94, 599-604.

Hiura, T., Khalid, H., Yamashita, H., Tokunaga, Y., Yasunaga, A., and Shibata, S. (1998). Immunohistochemical analysis of metal-lothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 83, 2361-2369. Korshunov, A., Sycheva, R., Timirgaz, V., and Golanov, A.

(1999). Prognostic value of immunoexpression of the chemo-resistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 45, 219-227.

Sparreboom, A., Danesi, R., Ando, Y., Chan, J., and Figg, W. D.

(2003). Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6, 71-84.

Abe, T., Mori, T., Wakabayashi, Y. et al. (1998). Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 40, 11-18.

Nagane, M., Asai, A., Shibui, S., Oyama, H., Nomura, K., and

Kuchino, Y. (1999). Expression pattern of chemoresistance-

related genes in human malignant brain tumors: a working knowledge for proper selection of anticancer drugs. Jpn J Clin

Oncol 29, 527-534.

Tanaka, S., Kamitani, H., Amin, M. R. et al. (2000). Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes. J Neurooncol 46, 157-171.

Tews, D. S., Nissen, A., Kulgen, C., and Gaumann, A. K.

(2000). Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 50, 227-237.

Tishler, D. M., Weinberg, K. I., Sender, L. S., Nolta, J. A., and Raffel, C. (1992). Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system. J Neurosurg 76, 507-512. Deng, L., Tatebe, S., Lin-Lee, Y. C., Ishikawa, T., and Kuo, M. T.

(2002). MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer 188. Treat.Res 112, 49-66.

174. Tishler, D. M., and Raffel, C. (1992). Development of multidrug resistance in a primitive neuroectodermal tumor cell 189. line. J Neurosurg 76, 502-506.

175. Muller, M., Meijer, C., Zaman, G. J. R. et al. (1994). Overexpression of the gene encoding the multidrug 190. resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad

Sci USA 91, 13033-13037.

176. Zaman, G. J. R., Flens, M. J., van Leusden, M. R. et al. (1994). Human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 191. 91, 8822-8826.

177. Nito, S. (1989). Enhancement of cytogenetic and cytotoxic effects on multidrug-resistant (MDR) cells by a calcium antagonist (verapamil). Mutat Res 227, 73-79. 192.

178. Rothenberg, M., and Ling, V. (1989). Multidrug resistance: Molecular biology and clinical relevance. JNCI 81, 907-910.

179. Mickley, L. A., Bates, S. E., Richert, N. D. et al. (1989). 193. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem

264, 18031-18040.

180. Abe, T., Koike, K., Ohga, T. et al. (1995). Chemosensitisation of 194. spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines over-expressing MRP or MDR. Br J Cancer 72, 418-423. 195.

181. Eichelbaum, M., Fromm, M. F., and Schwab, M. (2004). Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26, 180-185.

182. Burton, J. D. (2005). The MTT assay to evaluate chemosensi-

tivity. Methods Mol Med 110, 69-78. 196.

183. O'Brien, J., Wilson, I., Orton, T., and Pognan, F. (2000). Investigation of the Alamar Bluse (resazurin) fluorescent dye 197. for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267, 5421-5426. 198.

184. Shapiro, J. R., and Shapiro, W. R. (1985). The subpopulations and isolated cell types of freshly resected high grade human gliomas: Their influence on the tumor's evolution in vivo and 199. behavior and therapy in vitro. Cancer Metastasis Review 4, 107-124. 200.

185. Santini, M. T., and Rainaldi, G. (1999). Three-dimensional spheroid model in tumor biology. Pathobiology 67, 148-157.

186. Hamilton, G. (1998). Multicellular spheroids as an in vitro 201. tumor model. Cancer Lett 131, 29-34.

187. Kunz-Schughart, L. A., Kreutz, M., and Knuechel, R. (1998). Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp 202. Pathol 79, 1-23.

Desoize, B., Gimonet, D., and Jardiller, J. C. (1998). Cell culture as spheroids: an approach to multicellular resistance. Anticancer Res 18, 4147-4158.

Mueller-Klieser, W. (1997). Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol 273, C1109-C1123.

Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Von Hoff, D. D., Somerfield, M. R., for the ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays (2004). American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22, 3631-3638.

Haroun, R. I., Clatterbuck, R. E., Gibbons, M. C. et al. (2002). Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol 58, 115-123.

Shapiro, J. R., Yung, W.-K. A., and Shapiro, W. R. (1981). Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41, 2349-2359.

Shapiro, J. R., Pu, P.-Y., Mohamed, A. N., Galicich, J. H., Ebrahim, S. A. D., and Shapiro, W. R. (1993). Chromosome number and carmustine sensitivity in human gliomas. Cancer 71, 4007-4021.

Yung, W.-K. A., Shapiro, J. R., and Shapiro, W. R. (1982). Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42, 992-998. Fuller, C. E., Schmidt, R. E., Roth, K. A. et al. (2003). Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligoden-droglial/astrocytic features. J Neuropathol Exp Neurol 62, 1118-1128.

van den Bent, M. J. (2004). Diagnosis and management of oligodendroglioma. Semin Oncol 31, 645-652. Perry, J. R. (2001). Oligodendrogliomas: clinical and genetic correlations. Current Opinion in Neurology 14, 705-710. Fallon, K. B., Palmer, C. A., Roth, K. A. et al. (2004). Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63, 314-322. Buckner, J. C. (2003). Factors influencing survival in highgrade gliomas. Semin Oncol 30, 10-14.

van den, B. M., Chinot, O. L., and Cairncross, J. G. (2003). Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncol 5, 128-138. Stege, E. M., Kros, J. M., de Bruin, H. G. et al. (2005). Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103, 802-809.

van den Bent, M. J. (2004). Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol 17, 675-680.

PLATE 6.2 (Fig. 6.2)
PLATE 6.3 (Fig. 6.3)
PLATE 6.4 (Fig. 6.4)
Beating The Butt On Your Own

Beating The Butt On Your Own

Need To Stop Smoking? Are You Willing To Follow My Powerful Strategies To Stop Smoking And Vividly Transform Your Life Today? Proven Tips, Tools and Tactics To Stop Smoking And Live An Awesome Life You Always Wanted.

Get My Free Ebook


Post a comment